inspire.clinic: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.inspire.clinic in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “• “Semaglutide (similar to Ozempic) 2.5 mg vial” • “Tirzepatide (similar to Mounjaro) 10 mg vial” • “5 mg of semaglutide comparable to Ozempic. [sic]””

2. 2

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

inspire.clinic still has DNS records on 2026-08-09 — the apex resolves to Wix parking addresses and the www host to Wix CDN names — but both hosts returned HTTP 404 with a page titled "ConnectYourDomain Error | Wix.com", meaning the domain is registered but no site is connected to it. A disconnected Wix domain can be reconnected and says nothing definitive about the practice at the Grand Prairie address, so this is recorded as unknown rather than ceased-operations.

A milligram figure changes the nature of the comparison, and this is the only letter here where one appears. "Similar to Ozempic" is a claim about a molecule; "5 mg of semaglutide comparable to Ozempic" is a claim about a dose, and dose is what you are actually buying. The two do not map onto each other. An Ozempic pen is dispensed at a weekly dose that titrates — 0.25 mg, then 0.5, then 1, then 2 — while a compounded vial is sold as a total quantity of drug that you draw from, so a "2.5 mg vial" and a "5 mg vial" are amounts of raw material, not weekly doses, and how long either lasts depends entirely on where you land in titration. This is precisely where per-month price comparisons go wrong: two sellers quoting the same monthly figure may be shipping vials that differ several-fold in total milligrams, and a vial priced against a brand tells you nothing about how many weeks it covers. The right question at checkout is total milligrams, expected weekly dose, and therefore weeks of supply — three numbers, not one. FDA's finding is about the copy alone and makes no claim about what the vials contained. The site itself is currently unreachable: the domain resolves but no Wix site is connected to it.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence inspire.clinic failed to respond.